

MARKSANS PHARMA LIMITED

Regd. Office: 21st Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December 2009

Rs.in Lacs

Sr. No.	PARTICULARS	For the Quarter ended on		For the Period ended on		For the year ended on
		31.12.2009 (UNAUDITED)	31.12.2008 (UNAUDITED)	31.12.2009 (UNAUDITED)	31.12.2008 (UNAUDITED)	31st March 09 (AUDITED)
1	Income					
	a>. Net Sales/ Income from Operations	9,317.40	10,435.32	26,678.29	29,172.68	36,013.10
	b>. Other Operating Income	70.74	87.05	157.46	355.71	806.40
	Total Income	9,388.14	10,522.37	26,835.75	29,528.39	36,819.50
2	Expenditure					
	a>. (Increase)/Decrease in stock in trade	1,671.94	(17.14)	1,491.97	(105.51)	(859.69)
	b>. Consumption of Material & Purchases	4,668.53	7,933.73	17,550.43	19,397.19	25,151.46
	c>. Employee Cost	809.95	606.81	2,636.68	2,314.39	3,737.21
	d>. Depreciation	244.18	271.18	1,011.56	840.87	1,535.45
	e>. Other Expenditure	1,059.74	920.58	3,262.24	3,316.37	5,819.05
	Total Expenditure	8,454.34	9,715.16	25,952.88	25,763.31	35,383.48
3	Profit from Operations before other income					
	Interest & Exceptional Items (1-2)	933.80	807.21	882.87	3,765.08	1,436.02
4	Other Income	-	-	-	-	-
5	Profit before Interest & Exceptional item (3+4)	933.80	807.21	882.87	3,765.08	1,436.02
6	Interest	581.26	544.47	1,728.79	1,550.01	2,135.94
7	Profit after Interest but before Tax Exceptional items	352.54	262.74	(845.92)	2,215.07	(699.92)
8	Exceptional items	-	-	-	21.39	-
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	352.54	262.74	(845.92)	2,193.68	(699.92)
10	Tax Expenses -Earlier year Income tax	98.71	67.57	132.25	256.53	95.57
11	Net Profit/(loss) from Ordinary activities after tax(9-10)	253.83	195.17	(978.17)	1,937.15	(795.49)
12	Extraordinary Item- Minority Interest	(4.54)	12.18	25.20	94.23	40.05
13	Net Profit/ (Loss) for the period (11-12)	258.37	182.99	(1,003.37)	1,842.92	(835.54)
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.05	3,678.05	3,678.05	3,678.05	3,678.05
15	Reserve Excluding Revaluation Reserve as per	-	-	-	-	-
	Balance sheet of Previous Accounting year	-	-	-	-	10,000.66
16	a>. Earnings Per Share (Basic & Diluted)	0.07	0.05	(0.27)	0.53	(0.22)
	(before extraordinary items.Rs.)	-	-	-	-	-

	b>. Earnings Per Share(Basic & Diluted)	0.07	0.05	(0.27)	0.50	(0.23)	
	(after Extraordinary items- Rs.)	-	-	-	-	-	
17	Aggregate of Public Shareholding:	-	-	-	-	-	
	- Number of Shares	189,822,361.00	188,222,361.00	189,822,361.00	188,222,361.00	188,222,361.00	
	- Percentage of Holding	51.61%	51.17%	51.61%	51.17%	51.17%	1882.22361
18	Promoters and Promoter group Shareholdings	177,983,510.00	179,583,510.00	177,983,510.00	179,583,510.00	179,583,510.00	51.17
	a>. Pledged/Encumbered	-	-	-	-	-	
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	
	- Percentage of Holding	N.A	N.A	N.A	N.A	N.A	
	(as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	
	- Percentage of Holding	N.A	N.A	N.A	N.A	N.A	
	(as a % of the total share capital of the Company)	-	-	-	-	-	
	a>. Non-encumbered	-	-	-	-	-	
	- Number of Shares	177,983,510.00	179,583,510.00	177,983,510.00	179,583,510.00	179,583,510.00	
	- Percentage of Holding	100%	100%	100%	100%	100%	
	(as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	
	- Percentage of Holding	48.39%	48.83%	48.39%	48.83%	48.83%	
	(as a % of the total share capital of the Company)	-	-	-	-	-	

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.1.2010
- 2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 3 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 4 Marksans Pharma (U.K.) Ltd, a subsidiary of Marksans Pharma Ltd, acquired Relonchem Limited on 27.8.2008 Therefore to that extent the corresponding results of previous year are not comparable.
- 5 The Consolidated Financial Statement are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountant of India.
- 6 No Provision have been made during the year for Foreign Exchange Diffrence account in case of Foreign Currency Convertible Bond. The Management is of the opinion that the determination and crystallisation of liabilities is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the company

and therefore the same has been considered as a 'Contingnet Liability" as at 31st Decemberr,2009.

7 The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceuticals Ingridents and is managed as one entity, for its various activities and is governed by similar set of risk and returns.

8 There were no pending investor complaints at the beginning of the Quarter and 1 complaints were received during the Quarter, which have been attended and resolved and there was no complaint pending at the end of the Quarter.

9 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.

Date: January 29,2010

Visit us at www.marksanspharma.com

MARK SALDANHA
MANAGING DIRECTOR

	APR-DEC'08	APR-DEC'09	DIFF
MPL INDIA	173.05	123.36	49.69
MPLUK	108.83	101.37	7.46
NOVA	9.84	16.85	(7.01)
	<u>291.72</u>	<u>241.58</u>	50.14
	APR-SEP'08	APR-SEP'09	
MPL INDIA	122.32	85.60	36.72
MPLUK	58.78	76.79	(18.01)
NOVA	6.26	11.21	(4.95)
	<u>187.36</u>	<u>173.60</u>	13.76
	Oct -Dec'08	Oct -Dec'09	
MPL INDIA	50.73	37.76	12.97

MPLUK		50.05	24.58	25.47
NOVA		3.58	5.64	(2.06)
		<u>104.36</u>	<u>67.98</u>	<u>36.38</u>

		APR-DEC'08	APR-DEC'09	DIFF
BELL	GBP	7,325,318	8,072,835	-747517
REMONCHEM	GBP	6,938,886	6,006,945	931941
NOVA	AUD	2,734,682	3,746,512	-1011830
		<u>16,998,886</u>	<u>17,826,292</u>	<u>(827,406)</u>

		APR-SEP'08	APR-SEP'09	
BELL	GBP	3,996,300	4,910,318	-914018
REMONCHEM	GBP	3,119,784	4,916,166	-1796382
NOVA	AUD	1,677,735	2,669,494	-991759
		<u>8,793,819</u>	<u>12,495,978</u>	<u>(3,702,159)</u>

		Oct -Dec'08	Oct -Dec'09		
BELL	GBP	3,329,018	3,162,517	166501	13,320,080
REMONCHEM	GBP	3,819,102	1,090,779	2728323	218,265,840
NOVA	AUD	1,056,947	1,077,018	-20071	
		<u>8,205,067</u>	<u>5,330,314</u>	<u>2,874,753</u>	

		APR-DEC'08	INR	APR-DEC'09		DIFF
BELL	GBP	7,325,318	80.67	590933403	8,072,835	72.00 581244120 9,689,283
REMONCHEM	GBP	6,938,886	80.67	497459934	6,006,945	72.00 432500040 64,959,894
NOVA	AUD	2,734,682	37.12	98411396	3,746,512	45.00 168593040 (70,181,644)
		<u>16,998,886</u>		<u>1186804733</u>	<u>17,826,292</u>	<u>1,182,337,200</u> 4,467,533

	APR-SEP'08		APR-SEP'09				
BELL	3,996,300	82.60	330094380	4,910,318	78.14	383692249	(53,597,869)
REMONCHEM	3,119,784	82.60	257694158	4,916,166	78.14	384149211	(126,455,053)
NOVA	1,677,735	37.18	62678187	2,669,494	42.00	112118748	(49,440,561)
	<u>8,793,819</u>		<u>650,466,726</u>	<u>12,495,978</u>		<u>879,960,208</u>	<u>(229,493,482)</u>

	Oct -Dec'08		Oct -Dec'09				
BELL	3,329,018		260839023	3,162,517		197551871	63,287,152
REMONCHEM	3,819,102		239765775	1,090,779		48350829	191,414,946
NOVA	1,056,947		35733209	1,077,018		56474292	(20,741,083)
	<u>8,205,067</u>		<u>536,338,007</u>	<u>5,330,314</u>		<u>302,376,992</u>	<u>233,961,015</u>

- 0
0
0